Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series

Figures & data

Table 1. Baseline and follow-up disease and quality of life characteristics of patients undergoing secukinumab with concomitant results of psychiatric evaluation.

			BASELINE		W52		W104		W156
	Psychiatric Comorbidities	Previous Treatments	PASI	DLQI	PASI	DLQI	PASI	DLQI	PASI	DLQI	Psychiatric evaluation
1	Bipolar disorder/Delusion	Cs Mtx	17.5	28	0	4	0	4	0	2	Stability of the disorder
2	Major depression	Cs	20.5	20	0	4	0	4	0	4	Improvement
3	Anxiety with agoraphobia	Cs Mtx Eta	18	22	0	2	0	2	Na	Na	Improvement

Cs: ciclosporin, Mtx: Methotrexate, Eta: Etanercept.

Figure 1. Clinical psoriasis aspect before (a, b) and after 156 weeks (3 years) of treatment with secukinumab (c, d) in a patient affected by bipolar disorder with delusion episodes.

Figure 2. Severe scalp involvement before (a) and after 156 weeks (3 years) of treatment with secukinumab (b) in a patient affected by major depression.